Butterfly Network Director Phanstiel Buys $1.0 Million in Stock. Is This a Sign Investors Should Also Buy?
Butterfly Network (NYSE:BFLY) Director Louise S. Phanstiel purchased 115,200 shares for $1.0 million on August 14, 2026. The transaction was made at an average price of $8.68 per share. Post-transaction, Phanstiel holds 691,413 shares, representing 0.26% of the company. Butterfly Network has a market cap of $2.4 billion, with TTM revenue of $112.1 million and a net loss of $74.8 million.
How this was made
The 30-second read
Why it matters
The director's purchase could be interpreted as a vote of confidence, potentially prompting short‑term buying pressure.
Market read
Insider purchase is the primary new fact; may influence BFLY's short‑term price action.
What to watch
Company still reports a net loss; macro‑economic pressures on healthcare spending could offset bullish signal.
Background
Butterfly Network (BFLY) is a portable ultrasound device maker with a $2.4 B market cap and recent net losses.
Ticker impact
Form 4 disclosed director Louise Phanstiel bought 115,200 shares for $1.0 M, raising her stake to 0.26% of Butterfly Network.
Modest bullish bias; potential 2‑4% price lift over the next week.
Purchase size is material relative to float and aligns with typical insider‑buy signal strength.
Market effects
Highlights continued investor interest in digital‑health and portable ultrasound market.
Limited to U.S. healthcare technology investors.
Minor; reinforces broader trend of insider buying in med‑tech.
Counterpoint
Insider buying may simply reflect personal portfolio rebalancing, not a fundamental catalyst.
Key entities
- DirectorLouise S. Phanstiel
Chair of the Board of Directors at Myriad Genetics; director of Butterfly Network.
- CompanyButterfly Network, Inc.
Developer of portable ultrasound imaging devices.
